Outlook on the Companion Diagnostics Global Market to 2026 - by Product & Service, Technology, Indication, End-user and Region - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Companion Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global companion diagnostics market exhibited strong growth during 2015-2020. Looking forward, the market is expected to grow at a CAGR of 19.5% during 2021-2026.

Companies Mentioned

• Abbott Laboratories
• Agilent Technologies
• BioMerieux
• Danaher Corporation
• Roche Holding AG
• Myriad Genetics Inc.
• Siemens Healthcare
• Thermo Fisher Scientific Inc.

Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Companion diagnostics refer to a combination of tests and therapies that provide essential information about corresponding therapeutic products to deliver safe and effective medical care. These diagnostics also offer an in-depth understanding of disease biology and the mechanism of action (MOA), which help healthcare professionals determine the potential side effects or risks of a therapeutic product on the patient. At present, companion diagnostics are extensively utilized in oncology to deliver targeted therapies and personalized medicines to patients.

The growing prevalence of cancer, in confluence with the escalating demand for in-vitro diagnostics and targeted therapies, represents one of the key factors impelling the global companion diagnostics market growth. Apart from this, personalized healthcare (PHC) and precision medicine are also gaining traction in the treatment of cardiovascular, neurological, infectious and inflammatory diseases, which, in turn, is bolstering the growth of the market. Furthermore, the escalating demand for next-generation sequencing (NGS), the rising number of clinical trials and the increasing focus on the co-development of drugs and diagnostic technologies are contributing to the market growth. The introduction of new biomarkers, rising approvals of companion diagnostics and increasing collaboration between companies to develop novel companion diagnostic products are some of the other factors positively influencing the market growth. Currently, due to the spread of the coronavirus disease (COVID-19), diagnostic service providers are providing test services to healthcare providers. They are also utilizing companion diagnostics to detect the efficacy of COVID-19 drugs among patients undergoing oncology therapies.

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Companion Diagnostics Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Forecast

6 Market Breakup by Product & Service

7 Market Breakup by Technology

8 Market Breakup by Indication

9 Market Breakup by End-user

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure

15.2 Key Players

15.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/vav3ya